Gener ic Name OXYT OCIN

Brand Name Pitocin, Syntocin on

Action of the Drug As for endogeno us oxytocin,b ut with little vasopress in activity Stimulate s uterine contractio n Stimulate s lactating breast to eject milk

Indications

Preparations

By direct action on myofibrils, produces phasic contraction s characterist ic of normal delivery. Promotes milk ejection (letdown) re flex in nursing mother, thereby increasing flow (not volume) of milk; also facilitates flow of milk during period of breast engorgeme nt. Uterine sensitivity

5 units; 10 units/ mL inject ion in 1ml ampu le,via l orsyri nge i n comp atible IV sol ution.

Nursing Adverse reactions responsibiliti es Assessment & GI:Nausea and Drug Effects Vomiting Start Repiratory:Anoxi flow charts to a,Asphyxia record Others:Low APGAR score at maternal BP 5 mins. and other CV:Hypertention vital signs, ,increase heart I&O ratio, rate,systemic venous weight, returns,cardiac strength, output duration, and frequency of contractions, as well as fetal heart tone and rate, before instituting treatment. Monitor fetal heart rate and maternal BP

to oxytocin increases during gest ation period and peaks sharply before parturition. Not used for elective induction of labor.

and pulse at least q15min during infusion period; evaluate tonus of myometrium during and between contractions and record on flow chart. Report change in rate and rhythm immediately. Stop infusion to prevent fetal anoxia, turn patient on her side, and notifyphysici an if contractions

are prolonged (occurring at less than 2min intervals) and if monitor records contractions about 50 mm Hg or if contractions last 90 seconds or longer. Stimulation will wane rapidly within 23 min. Oxygen administratio n may be necessary. If local or regional (caudal,

spinal) anesthesia is being given to the patient receiving oxytocin, be alert to the possibility of hypertensive crisis (sudden intense occipital headache, palpitation, markedhyper tension, stiff neck, nausea, vomiting, sw eating, fever, photophobia, dilated pupils, bradycardia or tachycardia,

constricting chest pain). Check fundus frequently during the first few postpartum hours and several times daily thereafter. Inciden ce of hypersensitiv ity or allergic reactions is higher when oxytocin is given by IM or IV injection rather than by IV infusion (diluted solut ion).

Patient & Family Education Be aware of purpose and anticipated effect of oxytocin. Report sudden, severe headache immediately to healthcare providers AMOXI CILLIN Amoxil, Polymox

This drug is a semisyntheti c broad spectru m penici llin clos ely related to

Ear, nose, and throat infections due to Streptococcus species. GU Infections due to Escherichia coli, Proteus

Per Orem: usual dose of 500mg q8h or 500mg q12h. For gonococ cal

Note for any hypersen sitivity reaction Instruct clients that therapeut

Hypersensitivity, Nausea, Vomiting, Gastritis, Stomatitis

Ampicilli n. It binds to Penic illinbinding proteins in the cytoplas mic membra nes of bacteria , thus inhibitin g cellwall synthesi s. It also inhibits cell growth and cell division. It is better absorbe d than Ampicilli n.

miribalis, Enterococcus facecalis. Skin infections due to Streptococcus, S. pneumonia, Staphylococcus, or H. haemophilus Acute uncomplicated gonococcal infections due to Neisseria gonorrhoeae. In combination w ith omeprazole or lansoprazole to treat duodenal ulcers by eradicating Helicobacter pylori

infection s: 3 grams single dose

ic regimen must be complete d even if symptom s subside. Childs dose should not exceed maximum adult dose. Clients with GFR of 10-30 mL/min should receive 250500mg q12h. Monitor CBC,

renal and liver function tests. May be taken with food. Antibiotic resistanc e may occur if used without practition er consultati on as duration of therapy may not be complete d. Report: bleeding, sore

Mild to Moderat e Pain adult: P O Loading Dose 5 00 mg PO Mainten ance Dose 25 0 mg q6h prn

throat, rash, diarrhea, worsenin g of symptom s, lack of response Assessment & Drug Effects Assess patients who develop severe diarrhea and vomiting for dehydrati on and electrolyt e imbalanc e. Lab tests: With

CNS:Drowsiness, insomnia, dizziness, nervousness, confusion, headache. GI:Severe diarrhea, ulceration, and bleeding; nausea, vomiting, abdominal cramps, flatus, constipation, hepatic toxicity. Hematologic:Prolonged prothrombin time, severe autoimmune hemolytic anemia leukopenia, eosinophilia, agranulocytosis, thrombocytopenic Urogenital:Nephrotoxicit y, dysuria, albuminuria, Skin:Urticaria, rash, facial edema.

long-term therapy (not recomme nded) obtain periodic complete blood counts, Hct and Hgb, and kidney function tests.

SpecSenses:Eye irritation, loss of color vision (reversible), BodyWhole: Perspiration. CV:Palpitation. Respiratory:Dyspnea; acute exacerbation of asthma;

Patient & Family Education Discontin ue drug promptly if diarrhea, dark stools,

hematem esis, ecchymo ses, epistaxis, or rash occur and do not use again. Contact physician . Notify physician if persistent GI discomfor t, sore throat, fever, or malaise occur. Do not drive or engage in

potentiall y hazardou s activities until response to drug is known. It may cause dizziness and drowsine ss. Monitor blood glucose for loss of glycemic control if diabetic. Do not breast feed while taking

this drug without consultin g physician .

CEPHA LEXIN

keflex

Bactericidal: Inhibits synthesis of bacterial cell wall, causing cell death

Respiratory tract infections caused by S. pneumon iae, group A beta-hemolytic streptococci Dermatologi c infections caused by staphylococcu s, streptococcus Otitis media caused by S. pneumon iae, H. influenzae, streptococcus, staphylococcu s, Moraxella catarrhalis Bone infections caused by staphylococcu s, Proteus mirabilis GU infections caused by Escherichia coli, P.

Tablets: 250 and 500 mg, and 1 g. Capsules: 250, 333, 500 and 750 mg. Powder for Suspension: 125 and 250 mg/5 ml.

Take this drug with food. Refrige rate suspen sion; discard any drug after 14 days. Com plete the full course of this drug even if you feel better. This drug is prescri bed for this particul ar infectio n; do not

CNS: Headach e, dizziness, lethargy, paresth esias GI: Nausea, vomiting, diarrhea, anorexia, abdominal pain, flatulence, pseud omembranous c olitis, liver toxicity GU: Nephroto xicity Hematologic: Bone marrow depression Hypersensitivit y: Ranging from rash to fever to a naphylaxis; seru m sickness reaction Other: Superin fections

mirabilis, Klebs iella

selftreat any other infectio n. You may experie nce these side effects: Stomac h upset, loss of appetit e, nausea (take drug with food); diarrhe a; headac he, dizzine ss. Repo rt severe

diarrhe a with blood, pus, or mucus; rash or hives; difficult y breathi ng; unusual tiredne ss, fatigue; unusual bleedin g or bruising .
FERRO US SULFA TE Provides elemental iron component in the formation of hemoglobin. Iron deficiency anemia, hemodialysis-induced (treatment)Sodium ferric gluconate complex injection and iron sucrose injection are indicated for the treatment of iron deficiency anemia in patients undergoing chronic hemodialysis who are receiving supplemental erythropoietin Adult: Treatment : 400-600 mg daily in divided doses. Prevention: 200 mg daily. Child: Treatment : <6 yr or <22 kg: Not recommended. 6-12 yr: >22 kg: 200 mg daily; >44 kg: 200 mg bid >66 kg: 200 Nursing considerations Common: nausea, constipation, black stools

Use cautiously Uncommon: epigastric on long-term pain, vomiting, diarrhea, basis\ anorexia; liquid forms may temporarily stain Keep in mind teeth that GI upset may be related to dose.

therapy.{148}{149} Iron deficiency anemia (prophylaxis and treatment)Iron supplements are indicated in the prevention and treatment of iron deficiency anemia, which may result from inadequate diet, malabsorption, pregnancy, rapid growth during childhood, and/or blood loss. {105} Iron dextran and iron sorbitol are recommended for patients in whom iron deficiency has been determined, only after the cause has been corrected, if possible, and only when oral administration has been found unsatisfactory or impossible.

mg tid.

Between-meal doses are preferable, but can be given with some foods, although absorption may be decreased. Enteric-coated products reduce GI upset but also reduce amount of iron absorbed Be aware that oral iron may turn stools black. Although this unabsorbed iron is harmless, it could mask melenas.

Monitor hemoglobin and hematocrit levels and reticulocyte count during therapy, as ordered

Hyosci ne butylbr omide

BUSCO PAN

quatern ary ammoni um compou nd which, as an anticc agenhol inergit, has a ganglio n blocking compon ent. spasmol ytic. a powerfu l

Tab GIT & GUT spasm. Irritabl e bowel syndrome (IBS). Amp Acute GI, biliary & genito-urinary spasm, including biliary & renalcolic. As an aid in diagnostic & therapeutic procedures where spasm may be a problem eg gastroduodenal endoscopy & radiology.

Tab Adult & childn >12 yr 2 tab qds. IBS Initiall y 1 tab tds, may be increased if necessary. Chil dn 6-12 yr 1 tab tds. Amp Adult & adolescent >12 yr 1-2 amp (20-40 mg). Max 100 mg/day. Infants & childn Severe cases: 0.3-0.6 mg/kg body wt. Max 1.5 mg/kg body wt/day.

In case severe, unexplained abdominal pain persists or worsens, or occurs together with symptoms like fever, nausea, vomiting, changes in bowel movements, abdominal tenderness, decreased blood pressure, fainting or blood in stool, medical

Tachycardia, dizziness, dry mouth, dishydrosis, urinary retention. Tab Allergic reactions, dyspnea, painful red eye w/ loss of vision. Amp Anaphylacti c reactions, accomodation disorders, mydriasis, increased IOP, decreased BP, flushing.

smooth muscle relaxant , effective when given by mouth or by injection .

To be administered via slow IV, IM or SC inj several times daily.

advice should immediately be sought. Hyoscine may cause drowsiness: patients so affected should not drive or operate machinery. Patients should abstain from alcohol. However, as a quaternary ammonium compound with low lipid solubility, Buscopan cannot cross the blood/brain barrier easily and only rarely causes the central nervous system side

effects associated with atropine and hyoscine. After parenteral administration of Buscopan, patients with visual accommodatio n disturbances should not drive or operate machinery until vision has normalised. Elevation of intraocular pressure may be produced by the administration of anticholinergic agents such as Buscopan in patients with undiagnosed

and therefore untreated narrow-angle glaucoma. Patients should be advised to seek urgent ophthalmologi cal advice if they develop a painful, red eye with loss of vision after an injection of Buscopan. After parenteral administration, cases of anaphylaxis including episodes of shock have been observed. As with all drugs causing such reactions, patients receiving

Buscopan by injection should be kept under observation. One Buscopan tablet contains 41.2 mg sucrose, resulting in 392.6 mg sucrose per maximum recommended daily dose. Patients with the rare hereditary condition of fructose intolerance should not take this medicine. One Buscopan Forte tablet contains 138.5 mg lactose, resulting in 554 mg lactose per

METH ERGIN E

maximum recommended daily dose. Patients with the rare hereditary conditions of galactose intolerance e.g. galactosaemia , the Lapp lactose deficiency or glucosegalactose malabsorption , should not take this medicine. Methyler Methylergonov For routine 0.2 mg IM/IV Instruct gonovine ine management after q2-4hr PRN; patient to Maleate maleate(methe delivery of the not to exceed 5 take rgine) is an placenta; postpartum doses, THEN medicatio ergot alkaloid atony and 0.2-0.4 mg PO that stimulate hemorrhage; q6-8hr PRN for n as smooth muscle subinvolution. Under 2-7 days directed; tissue.Becaus full obstetric do not e the smooth supervision, it may be Administer IV only in skip or muscle of the given in the second emergency uterus stage of labor double up because of is especially following delivery of on sensitive to the anterior shoulder potential for missed Hypertension &

CNS: dizziness, hallucinations, headache, paresthesias, seizure CV: hypertension, palpitations, temporary chest pain, thrombophlebitis GI: diarrhea, foul

this drug ,it is used postpartally to stimulate the uterus to contract in order to decrease blood loss by clamping off uterine blood vessels and to promote the involution process .In addition the drug has vasoconstrictiv e effect on all blood vessels,especi ally the larger arteries.

CVA Administer over >1 minute and monitor BP

doses. If a dose is missed, omit it and return to regular dose sch edule. Advise patient that medicatio n may cause menstrual -like cramps Caution patient to avoid smoking, because nicotine c onstricts blood vessels.

taste, nausea, vomiting MISC: leg cramps, dyspnea, diaphoresis

Instruct patient to notify hea lth care professio nal if infection develops, as this may cause increased sensitivity to the medicatio n. Credits: DEXTR OSE Dextrose is a monosacchari de that is used as a source of calories and water for hydration. It helps to reduce loss of body protein and nitrogen. It PO Hypoglyca emia 10-20 g as a single dose. May repeat in 10 mins if needed. IV Hyp oglycaemia As 25% soln: 40100 mL.Hyperkalae Overt or known subclinical DM. Patients with carbohydrate intolerance. IV admin of dextrose may result in hypokalaemia, Venous thrombosis, phlebitis, hypovolemia, hypervolemia, dehydration, oedema, fever, mental confusion, unconsciousness, hyperosmolar syndrome, hyperglycaemia, hypokalaemia, acidosis, hypophosphataemia,

also promotes glycogen deposition in the liver. When used with insulin, it stimulates the uptake of potassium by cells, especially in muscle tissue, thus lowering serum potassium levels. Absorption: Ra pidly absorbed from the small intestine when taken orally. Metabolism: M etabolised to carbon dioxide and water.

mia 25-50 g w/ 10 u of regular insulin. Repeat if needed.

hypophosphat aemia and hypomagnese mia. Prolonged infusion of isotonic dextrose solutions may cause water intoxication. Production of insulin may be adversely affected by prolonged parenteral nutrition with dextrose solutions. Rapid admin of hypertonic dextrose solutions may result in hyperglycaemi a and hyperosmolar syndrome. Monitor for signs of mental confusion or

hypomagnesemia, polyuria, glycosuria, ketonuria, nausea, diarrhoea, polydipsia, vein irritation, tissue necrosis, pulmonary oedema, tachypnoea.

Nalbup hine hydroc

NUBAIN

Unknown. Binds with opiate

* Moderate to severe pain * Adjunct to balanced

Injection: 10 mg/ml, 20 mg/ml, **510

loss of consciousnes s. Monitor blood and urinary glucose regularly. Caution when used in very low birth weight infants. Abrupt withdrawal may lead to rebound hypoglycaemi a. Risk of thrombosis when hypertonic (>10%) solutions are administered through peripheral veins. Caution when used parenterally in pregnant women. CNS: headache, sedation,

CNS: headache, sedation, dizziness, vertigo, nervousness,

hloride

receptors in the CNS, altering perception of and emotional response to pain.

anesthesia

mg IV/IM/SQ every 36 hours

dizziness, vertigo, nervousness, depression, restlessness, crying, euphoria, hostility, confusion, unusual dreams, hallucinations, speech disorders, delusions CV: hypertension, hypotension, tachycardia, bradycardia EENT: blurred vision, dry mouth GI: cramps, dyspepsia, bitter taste, nausea, vomiting, constipation, biliary tract spasms GU: urinary urgency

depression, restlessness, crying, euphoria, hostility, confusion, unusual dreams, hallucinations, speech disorders, delusions CV: hypertension, hypotension, tachycardia, bradycardia EENT: blurred vision, dry mouth GI: cramps, dyspepsia, bitter taste, nausea, vomiting, constipation, biliary tract spasms GU: urinary urgency Respiratory: respiratory depression, dyspnea, asthma, pulmonary edema Skin: pruritus, burning, urticaria, clamminess, diaphoresis

midazol DORMIC May potentiate am UM theeffect of GABA,depress the CNS, andsuppress the spread of seizure activity

Preoperative sedation/anxiolysis, induction of general anaesthesia. Sedative hypnotic for gastrointestinal endoscopy, bronchoscopy, dentistry and surgery done under regional anaesthesia. In ICU for artificial ventilation which requires long term sedation. Patients with acute narrow angle glaucoma.

Respiratory: respiratory depression, dyspnea, asthma, pulmonary edema Skin: pruritus, burning, urticaria, clamminess, diaphoresis Standard Intra Less frequent or lower doses Muscular (IM) dose is 0.07 to should be 0.08 mg/kg, i.e. instituted in higher risk 3.6 mg of adult and midazolam. paediatric The standard surgical Intra Venous patients, (IV) dose is elderly, 0.01 to 0.07 debilitated mg/kg i.e. patients, 2.5mg of patients with COPD, midazolam. For induction of patients with chronic renal general failure and anaesthesia, CHF, patients

CNS: Oversedation,drowsiness, amnesia,headache, involuntarymovements, nystagmus, paradoxical behaviour or excitement. Cardiovascular: Variationsin blood pressure and pulserate. Respiratory: Apnea,decreased respiratory rate,hiccups. Gastrointestinal: Nausea,vomiting

Intrathecal or epidural the administration. recommended incremental dose is 0.1 to 0.5 mg/kg following an initial dose of 0.08 mg/kg.

with uncompensat ed acute illness, such as severe fluid or electrolyte disturbances. Use in Pregnancy or during lactation is only recommended if the potential benefits far outweigh the potential risk. Titrate slowly in adult or pediatric patients when indicated for sedation/ anxiolysis/am nesia. After a longterm administration,

do not discontinue abruptly. Epineph lidocaine HCl in rine 5% dextrose Type 1 antiarrhythmic: decreases diastolic depolarization, decreasing automaticity of ventricular cells; increases ventricular fibrillation threshold. Local anesthetic: blocks the generation and conduction of action potentials in sensory nerves by reducing sodium permeability, reducing height and rate of rise of the action As antiarrhythmic: 5mL Management of acute (100mg/5mL) ventricular arrhythmias during cardiac surgery and MI (IV use). Use IM when IV administration is not possible or when ECG monitoring is not available and the danger of ventricular arrhythmias is great (single-dose IM use, for example, by paramedics in a mobile coronary care unit) As anesthetic: Infiltration anesthesia, peripheral and sympathetic nerve blocks, central nerve blocks, spinal and caudal anesthesia, retrobulbar and transtracheal injection; topical anesthetic for skin Check drug concentration carefully; many concentrations are available. Reduce dosage with hepatic or renal failure. Continuously monitor response when used as antiarrhythmic or injected as local anesthetic. Maintain lifesupport equipment, and have vasopressors on standby if severe adverse reaction (CNS, CV, or respiratory) Dizziness, Paraesthesia, Drowsiness, Confusion, Respiratory depression, Convulsion

potential, increasing excitation threshold, and slowing conduction velocity.

disorders and accessible mucous membranes

occurs when lidocaine is injected. Establish safety precautions if CNS changes occur; have IV diazepam or short-acting barbiturate (thiopental, thiamylal) on standby in case of convulsions. Monitor for malignant hyperthermia (jaw muscle spasm, rigidity); have life-support equipment and IV dantrolene on standby. Titrate dose to minimum needed for cardiac stability, when using

lidocaine as antiarrhythmic . Reduce dosage when treating arrhythmias in CHF, digitalis toxicity with AV block, and geriatric patients. Monitor fluid load carefully; more concentrated solutions can be used to treat arrhythmias in patients on fluid restrictions. Have patients who have received lidocaine as a spinal anesthetic remain lying flat for 612 hr afterward, and ensure that

they are adequately hydrated to minimize risk of headache. Check lidocaine preparation carefully; epinephrine is added to solutions of lidocaine to retard the absorption of the local anesthetic from the injection site. Be sure that such solutions are used only to produce local anesthesia. These solutions should be injected cautiously in body areas supplied by end arteries

and used cautiously in patients with peripheral vascular disease, hypertension, thyrotoxicosis, or diabetes. Use caution to prevent choking. Patient may have difficulty swallowing following use of oral topical anesthetic. Do not give food or drink for 1 hr after use of oral anesthetic. Treat methemoglobi nemia with 1% methylene blue, 0.1 mg/kg, IV over 10 min. Apply lidocaine ointments or

creams to a gauze or bandage before applying to the skin. Monitor for safe and effective serum drug concentrations (antiarrhythmi c use: 15 mcg/mL). Doses > 610 mcg/mL are usually toxic. VITAMI NA Aquasol A Vitamin A is effective for treatment of conditions such as acne or lung diseases, or for treatment of eye problems, wounds, or dry or wrinkled skin not caused by lack of vitamin A Vitamin A injection is effective for the treatment of vitamin A deficiency. Adequate Intake (AI) levels of vitamin A for infants have been established: birth to 6 months, 400 mcg/day (1300 units); 7 to 12 months, 500 mcg/day (1700 units). Teach the family about the Vitamin A toxicity. Caution pregna nt patient about the taking rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing

has not been proven. Although vitamin A is being used to prevent certain types of cancer, some experts feel there is not enough information to show that this is effective, particularly in well-nourished individuals

of vitamin A. Teach patient that over consum ption of vitamin A can cause nausea , irritabilit y and blurred vision. Teach patient that Vitamin A must be avoided from direct sunlight exposu re. Instruct patient/

family that if there is a sign of over dosage of vitamin A, it must be reporte d immedi ately to the physici an. Share:

Mefena mic acid

DOLFEN Mefenamic AL acid is a nonsteroidal antiinflammatory drug (NSAID) which is an anthranilic acid derivative. It exhibits antiinflammatory, analgesic and

Relief of mild to moderately severe somatic & neuritic pain; headache, migr aine, traumatic pain, postpartum pain, post-op pain, dental pain, & in pain & fever followi ng various inflammatory conditions;

250-500 mg tid. Max: 7 days.

Use with caution in patients with peptic ulcer, liver and kidney impairment, heart failure and high blood pressure. Effects on the

Gastrointestinal: Diarrhea, nausea, vomiting, abdominal pain, anorexia, heartburn, gastritis, flatulence, peptic ulcer. Hematologic: Occasionally, leucopenia, eosinophilia, thrombocytopenic purpura,

antipyretic activity by inhibiting prostaglandin synthesis in body tissues. Unlike most other NSAIDs, mefenamic acid appears to compete with prostaglandins for binding at the prostaglandin receptor site and thus, potentially affect prostaglandins that have already been formed.

dysmenorrhea; meno rrhagia accompanied by spasm or hypogastric pain.

Ability to Drive or Operate Machinery: Mefenamic acid may impair the ability to perform activities requiring mental alertness or physical coordination. Impairment of Fertility: Altho ugh there are no adequate and wellcontrolled studies to date in humans, mefenamic acid has been shown to have adverse effects in animals during reproduction studies. Use in pregnancy & lactation: Mefe

agranulocytosis, pancytopenia and bone marrow hypoplasia. Mefenamic acid can inhibit platelet aggregation and may prolong bleeding time. Nervous System: Occasionally, drowsiness, nervousness, dizziness, fatigue, anxiety and insomnia. Ocular and Otic: Blurred vision, eye irritation and rarely, reversible loss of color vision. Renal Effects: Papillary necrosis and acute interstitial nephritis. Renal impairment accompanied by macular rash, hematuria, dysuria and mild elevations in BUN have also been reported. Hepatic Effects: Mild hepatotoxicity has been reported. Others: Urticaria, rash, facial edema,

namic acid palpitation, dyspepsia should be and acute pancreatitis used in pregnancy only when clearly needed. Mefenamic acid is distributed into milk and because of its potential for adverse effects on the cardiovascular system in infants, a decision should be made whether to discontinue nursing or discontinue medication with mefenamic acid. Use in children: Safet y and efficacy of mefenamic acid in

Cefuro xime Axetil Cefuro xime Sodium

Cefuroxi me Axetil (Ceftin [P.O.]) Cefuroxi me Sodium (Zinacef [Parente ral])

Secondgeneration cephalosporin that inhibits cell-wall synthesis, promoting osmotic instability; usually bactericidal.

* Pharyngitis, tonsillitis, infections of the urinary and lower respiratory tracts, and skin and skinstructure infections caused by Streptococcus pneumoniae and S. pyogenes, Haemophillus influenzae, Staphylococcus aureus, Escherichia coli, Moraxella catarrhalis (including beta-lactamaseproducing strains), Neisseria gonorrheae, and Klebsiella and Enterobacter species. * Serious lower respiratory tract infections, UTIs, skin and skin-structure infections, bone and joint infections, septicemia,

Cefuroxime Axetil Suspension: 125 mg / 5 ml, 250 mg / 5 ml Tablets: 125 mg, 250 mg, 500 mg Cefuroxime Sodium Infusion: 750 mg, 1.5 g premixed, frozen solution Injection: 750 mg, 1.5 g

children <14 years have not been established. * Before administering, make sure patient is not allergic to penicillins or cephalosporin s. * Absorption of cefuroxime axetil is enhanced by food. * Cefuroxime axetil tablets may be crushed if swallowing is a difficulty. Cefuroxime axetil tablets may be dissolved in small amounts of apple, orange or grape juice, even chocolate

CV: phlebitis, thrombophlebitis GI: pseudomembranous colitis, nausea, anorexia, vomiting, diarrhea Hematologic: transient neutropenia, eosinophilia, hemolytic anemia, thrombocytopenia Skin: maculopapular and erythematous rashes, urticaria, pain, induration, sterile abscesses, temperature elevation, tissue sloughing at intramuscular injection site Other: hypersensitivity reactions, serum sickness, anaphylaxis.

meningitis, and gonorrhea * Uncomplicated UTIs * Otitis Media * Pharyngitis and Tonsillitis * Perioperative Prevention * Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi * Secondary bacterial infection of acute bronchitis * Uncomplicated gonorrhea * Acute bacterial maxillary sinusitis caused by Streptococcus pneumoniae or Haemophilus influenza (only strains that dont produce beta-lactamase)

milk. However, drugs bitter taste is difficult to mask even with food. * High-fat meals increased drug bioavailability. * ALERT! Cef uroxime axetil film-coated tablet and oral suspension are not bioequivalent. * If large doses are given, therapy is prolonged, or patient is at high risk, monitor patient for signs and symptoms of superinfection. * Unlike other second generation

cephalosporin s, cefuroxime can cross the blood-brainbarrier. * ALERT! Do not confuse with other cephalosporin s that sound alike. * Take medication as prescribed, even after feeling better. * Take oral form with food. * If suspension is being used, shake the container well before measuring dose. * Notify prescriber about rashes or superinfection s.

* Notify prescriber about loose stools or diarrhea.

BORELA, LIEZL T. RR21-BSN2